2021 DORIS definition of remission in SLE: final recommendations from an international task force

Ronald F van Vollenhoven, George Bertsias, Andrea Doria, David Isenberg, Eric Morand, Michelle A Petri, Bernardo A Pons-Estel, Anisur Rahman, Manuel Francisco Ugarte-Gil, Alexandre Voskuyl, Laurent Arnaud, Ian N Bruce, Ricard Cervera, Nathalie Costedoat-Chalumeau, Caroline Gordon, Frédéric A Houssiau, Marta Mosca, Matthias Schneider, Michael M Ward, Graciela AlarconMartin Aringer, Anka Askenase, Sang-Cheol Bae, Hendrika Bootsma, Dimitrios T Boumpas, Hermine Brunner, Ann Elaine Clarke, Cindy Coney, László Czirják, Thomas Dörner, Raquel Faria, Rebecca Fischer, Ruth Fritsch-Stork, Murat Inanc, Søren Jacobsen, David Jayne, Annegret Kuhn, Bernadette van Leeuw, Maarten Limper, Xavier Mariette, Sandra Navarra, Mandana Nikpour, Marzena Helena Olesinska, Guillermo Pons-Estel, Juanita Romero-Diaz, Blanca Rubio, Yehuda Schoenfeld, Eloisa Bonfá, Josef Smolen, Y K Onno Teng, Angela Tincani, Michel Tsang-A-Sjoe, Carlos Vasconcelos, Anne Voss, Victoria P Werth, Elena Zakharhova, Cynthia Aranow

194 Citationer (Scopus)

Abstract

OBJECTIVE: To achieve consensus on a definition of remission in SLE (DORIS).

BACKGROUND: Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation.

METHODS: Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on.

RESULTS: Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics.

CONCLUSION: The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.

OriginalsprogEngelsk
Artikelnummere000538
TidsskriftLupus science & medicine
Vol/bind8
Udgave nummer1
ISSN2053-8790
DOI
StatusUdgivet - nov. 2021

Fingeraftryk

Dyk ned i forskningsemnerne om '2021 DORIS definition of remission in SLE: final recommendations from an international task force'. Sammen danner de et unikt fingeraftryk.

Citationsformater